CISATRACURIUM BESYLATE INJECTION SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CISATRACURIUM (CISATRACURIUM BESYLATE)

から入手可能:

ACCORD HEALTHCARE INC

ATCコード:

M03AC11

INN（国際名）:

CISATRACURIUM

投薬量:

2MG

医薬品形態:

SOLUTION

構図:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

10 ML

処方タイプ:

Prescription

治療領域:

NEUROMUSCULAR BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0133260001; AHFS:

認証ステータス:

APPROVED

承認日:

2016-09-01

製品の特徴

_Cisatracurium Besylate Injection_
_ Product Monograph Page 1 of 32 _
PRODUCT MONOGRAPH
PR
CISATRACURIUM BESYLATE INJECTION
Solution for injection; 20 mg / 10 mL (2 mg / mL) cisatracurium (as
cisatracurium besylate)
(Multiple dose vial)
House Standard
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
Sterile solution
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR WITH ITS
ACTIONS, CHARACTERISTICS, AND HAZARDS.
Accord Healthcare Inc.
3535 boul. St. Charles, Suite 704
Kirkland, QC H9H 5B9
Canada
Submission Control No: 180494
Date of Preparation:
August 31, 2016
_Cisatracurium Besylate Injection_
_ Product Monograph Page 2 of 32 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
................................................................................................3
WARNINGS AND
PRECAUTIONS...............................................................................4
ADVERSE
REACTIONS.................................................................................................9
DRUG INTERACTIONS
................................................................................................10
DOSAGE AND ADMINISTRATION
............................................................................11
OVERDOSAGE
..............................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
..........................................................17
STORAGE AND
STABILITY........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.....................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................